Potsdam, Germany, January 20, 2012
Signature Diagnostics to Present a novel Companion Diagnostic Product Predicting Response to Cetuximab in Colorectal Cancer at the ASCO 2012 Gastrointestinal Cancer Symposium in San Francisco
Potsdam, Germany, January 20, 2012 Signature Diagnostics to Present Detector C 2.0 - A Blood Test for Early Detection of Colorectal Cancer at the ASCO 2012 Gastrointestinal Cancer Symposium in San Francisco
Potsdam, Germany, November 24, 2011 Signature Diagnostics to Present at the 23rd Annual Piper Jaffray Health Care Conference
Potsdam, Germany, April 6, 2011 Signature Diagnostics to Present a novel Companion Diagnostic Product Predicting Response to Cetuximab in Colorectal Cancer at the 102nd AACR Meeting in Orlando
Potsdam, Germany, December 7, 2010 Signature Diagnostics Receives Extended Patent Protection for its Proteasome-Complex Inhibitors
Potsdam, Germany, October 27, 2010 Signature Diagnostics to Present Company's Blood-Based Colorectal Cancer Screening Strategy at the 18th UEGW Congress in Barcelona
• Advantages of Detector C and Detector C/Plus in early detection of CRC
Potsdam, Germany, October 20, 2010 Signature Diagnostics to Present at Upcoming 2010 Life Science & Health Care Venture Summit in New York City
Potsdam, Germany, October 8, 2010 Signature Diagnostics to Present Company's Newest Product in Colorectal Cancer Screening at the 35th ESMO Congress in Milan
• Blood-based screening test, Detector C/Plus, uses a panel of 1,802 RNA markers for increased sensitivity and specificity
Potsdam, Germany, September 30, 2010 Signature Diagnostics Appoints Rainer Kramer to Chief Business Officer and Member of the Management Board
Potsdam, Germany, July 8, 2010 Signature Diagnostics Presents Positive Colorectal Screening Study Results at the 12th World Congress on Gastrointestinal Cancer in Barcelona
Santa Clara, Calif. and Potsdam, Germany, June 28, 2010 Signature Diagnostics to Use Affymetrix Microarray Technology for Advanced Colorectal Cancer Tests
Signature Diagnostics will commercialize first microarray-based products for detecting and predicting progression of colorectal cancer
Potsdam, Germany, June 4, 2010 Signature Diagnostics Announces Positive Study Results Using Predictor C to Predict Disease Progression and Therapeutic Risk in Colorectal Cancer Patients
Potsdam, Germany, June 4, 2010 Signature Diagnostics Announces Positive Study Results for Detector C, Its Non-Invasive, Blood-Based IVD Screening Test for Early Detection of Colorectal Cancer
Potsdam, Germany, November 26, 2008 Signature Diagnostics announces the recruitment of the first 2.000 Patients with Colorectal Cancer into its Multi-Centre Prospective Diagnostic Clinical Study (MSKK)
Potsdam,
August 12, 2008 Signature Diagnostics Raised 5.1 Mio EURO in a Series C Financing Round
Potsdam,
February 13, 2008 Herman Spolders, CEO of OncoMethylome Sciences, joins Signature Diagnostics’ Supervisory Board
Potsdam (Germany) / Liege (Belgium), January 30, 2008 OncoMethylome Sciences SA to Initiate a Large Colorectal Cancer Clinical Trial and Acquire Minority Interest in Signature Diagnostics AG.
Potsdam, 19 October 2007 Signature Diagnostics AG announced today that the company has developed a new gene expression classifier, that predicts the risk of recurrence and metastasis (progression of disease) in stage I and II colorectal cancer. Presenting at the Annual Conference of the AGD 2007 in Potsdam, Dr. Hans-Peter Adams gave an overview about the molecular and clinical performance of the new classifier. The molecular classifier named Predictor-C is a powerful new prognostic tool to assess the individual risk of metastasis of stage I and II colorectal cancer patients directly after surgery and will have a profound impact on the treatment decision for patients and physicians.
Potsdam,
21 March 2007 Signature Diagnostics AG has been certified by EN ISO 9001/12.2000 (general quality management) and EN ISO 13485/07.2003 (development of in-vitro diagnostics - IVD).
Potsdam / Berlin, 22 February 2007 Signature Diagnostics AG and the Vivantes Netzwerk für Gesundheit GmbH (Berlin) announce a Clinical Research Collaboration in Colorectal Cancer
Potsdam, 13 September 2006 Signature Diagnostics announces a Clinical Research Collaboration with OncoMethylome Sciences
München
/ Potsdam, 01 September 2006 Signature Diagnostics introduces the MARVIN EDC-CDM System in its Multi-Centre Diagnostic Colorectal Cancer Trial for e-Capturing of Clinical Data
Dresden / Potsdam, 29 August 2006 Technical University Dresden and Signature Diagnostics AG announce Research Collaboration
Basel / Potsdam, 01 November 2005 Signature Diagnostics selects Genedata’s Computational Solution for High Throughput Cancer Diagnostics Application
Potsdam, 22 September 2005 Signature Diagnostics announces that it has appointed Dr. Anne-Fabienne Weitsch as Vice President of Business Development.
Potsdam, 20 June 2005 Junghanns: Stärkung für Potsdamer Biotech-Standort
Wirtschaftsminister übergab Zuwendungsbescheid an Signature Diagnostics AG
Potsdam / Berlin, 04 March 2005 Signature Diagnostics koordiniert ein Highlight-Projekt des Bundesministeriums für Bildung und Forschung (BMBF) mit einem Volumen von 1,7 Millionen €. Im Verbund mit der Scienion AG, der MicroDiscovery GmbH und dem Institut für Biomedizinische Technik (IBMT) wird im Rahmen von InnoRegio-BioHyTec ein neuartiger Genchip für die prädiktive Diagnostik von Patienten mit Darmkrebs entwickelt.
